



ABN 79 009 109 755

Bone Medical

8 November 2005

ASX/MEDIA RELEASE

Bone Medical Limited (ASX: BNE, "Bone") today announced the appointment of Paul Hopper as Executive Chairman of the Company.

Mr Hopper is the existing Chairman of Bone and assumes his new role with immediate effect.

His appointment follows the decision of the Board of Bone not to renew the contract of Chief Executive Officer Michael Redman.

Mr Hopper said the Company intended to continue its focus on the development and commercialisation of Bone's portfolio of pharmaceuticals to treat bone disease.

"I am delighted to assume this role at Bone and look forward to overseeing the development of the company's products for the benefit of shareholders," he said.

Mr Hopper has 25 years experience in listed companies in both Australia and the US, primarily in the healthcare and biotechnology sectors. He is the Chairman of Innovate Oncology, a US-listed biotechnology company, CEO of Evolve Oncology, and a Director of Advanced Biotherapy, Inc in addition to a consultant to various other international biotechnology companies.

Bone will provide shareholders with a comprehensive update on the Company's operational activities and corporate strategy at its annual meeting on 28 November in Perth.

-ENDS-

For more information about Bone Medical, please contact:

Paul A. Hopper
Executive Chairman
Bone Medical
Tel (Aust): +61 8 9355 5123
Mobile (USA): +1 858 200 5636

Or visit: www.bonemedical.com